{"created":"2024-07-26T04:43:50.341144+00:00","id":2000693,"links":{},"metadata":{"_buckets":{"deposit":"b94b481f-0645-43d9-8c49-fc7158bf3c11"},"_deposit":{"created_by":9,"id":"2000693","owner":"9","owners":[9],"pid":{"revision_id":0,"type":"depid","value":"2000693"},"status":"published"},"_oai":{"id":"oai:miyazaki-u.repo.nii.ac.jp:02000693","sets":["72","72:30"]},"author_link":["7997"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2024-07-01","bibliographicIssueDateType":"Issued"},"bibliographic_titles":[{"bibliographic_title":"International Journal of Hematology","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal erythrocytosis. A phase 2 study reported that ropeginterferon alfa-2b is a well-tolerated and effective treatment for PV in Japanese patients. This post hoc analysis of the phase 2 data further evaluated outcomes in patients at low risk of thrombosis (low-risk PV). Among 20 patients with low-risk PV, 60.0% (12/20) and 85.0% (17/20) achieved < 45% hematocrit by weeks 24 and 52, respectively. The proportion of responders with complete hematologic response (CHR) was 60.0% (12/20) at week 52, and the median time to response was 11.9 months. The mean JAK2 V617F allele burden decreased from 75.8% at baseline to 53.7% at week 52. No patient experienced thrombosis or bleeding episodes. All patients experienced treatment-emergent adverse events (TEAEs) related to ropeginterferon alfa-2b, but no grade ≥ 3 TEAEs or deaths related to ropeginterferon alfa-2b occurred, and no new safety concerns arose. This analysis indicated that ropeginterferon alfa-2b may be an effective treatment option for Japanese patients with low-risk PV.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Citation:Shimoda, K., Qin, A., Komatsu, N. et al. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b. Int J Hematol (2024). https://doi.org/10.1007/s12185-024-03804-1","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Science and Business Media LLC","subitem_publisher_language":"en"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s12185-024-03804-1","subitem_relation_type_select":"DOI"}}]},"item_10001_rights_15":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0925-5710","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"1865-3774","subitem_source_identifier_type":"EISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"0000000106573887","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"https://isni.org/isni/0000000106573887"}],"affiliationNames":[{"affiliationName":"宮崎大学","affiliationNameLang":"ja"},{"affiliationName":"University of Miyazaki","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Shimoda, Kazuya","creatorNameLang":"en"},{"creatorName":"下田, 和哉","creatorNameLang":"ja"},{"creatorName":"シモダ, カズヤ","creatorNameLang":"ja-Kana"},{"creatorName":"Shimoda, Kazuya","creatorNameLang":"en"}],"familyNames":[{"familyName":"Shimoda","familyNameLang":"en"},{"familyName":"下田","familyNameLang":"ja"},{"familyName":"シモダ","familyNameLang":"ja-Kana"},{"familyName":"Shimoda","familyNameLang":"en"}],"givenNames":[{"givenName":"Kazuya","givenNameLang":"en"},{"givenName":"和哉","givenNameLang":"ja"},{"givenName":"カズヤ","givenNameLang":"ja-Kana"},{"givenName":"Kazuya","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"7997","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"90311844","nameIdentifierScheme":"e-Rad_Researcher","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=90311844"}]},{"creatorNames":[{"creatorName":"Qin, Albert","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Komatsu, Norio","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kirito, Keita","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-07-26"}],"filename":"s12185-024-03804-1.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","url":{"label":"article","objectType":"fulltext","url":"https://miyazaki-u.repo.nii.ac.jp/record/2000693/files/s12185-024-03804-1.pdf"},"version_id":"e26f69bd-8d33-4824-935c-834383784e33"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Hematologic response","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"JAK2 V617F allele burden","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Low-risk","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Polycythemia vera","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ropeginterferon alfa-2b","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"9","path":["72","30"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-07-26"},"publish_date":"2024-07-26","publish_status":"0","recid":"2000693","relation_version_is_last":true,"title":["Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b"],"weko_creator_id":"9","weko_shared_id":-1},"updated":"2025-01-07T04:29:56.555301+00:00"}